Drugs / E-B-FAHF-2
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03992469 | Feb 2023 → Feb 2026 overdue | Crohn disease | Icahn School of Medicine at Mount Sinai | Active not recruiting | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT06103656 | Aug 2016 → Jul 2020 | food allergy | New York Medical College | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02879006 Comparator | Aug 2016 → Nov 2020 | food allergy | Xiu-Min Li | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E-B-FAHF-2 | “The study team's current proposed study uses the same investigational agent, E-B-FAHF-2, being studied for food allergy under an active IND, and seeks to determine if this...” NCT03992469 ↗3“This study aimed to determine the safety and efficacy of enhanced, butanol purified Food Allergy Herbal Formula-2 (E-B-FAHF-2) for inducing remission in subjects undergoing...” PMID 37087097 ↗ Apr 2023 “E-B-FAHF-2 Chinese herbal therapy” NCT02879006 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “E-B-FAHF-2 Chinese herbal therapy” NCT02879006 ↗ |
| Route | Oral | “Oral E-B-FAHF-2” NCT03992469 ↗ |